Aurobindo Pharma Limited (AUROPHARMA)

Name: Aurobindo Pharma Limited (AUROPHARMA) — histórico de demonstrações financeiras
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

Histórico de receita, lucros e fluxo de caixa das demonstrações financeiras oficiais.

Healthcare · Wall Street (EUA) · Última atualização: 2026-09-20

Aurobindo Pharma Limited, a pharmaceutical company, develops, manufactures, and commercializes generic pharmaceuticals in India, the United States, Europe, and internationally. The company manufactures a range of finished formulation products in various forms, such as oral solids, liquids, injectables for generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients for CNS, anti-retroviral, cardiovascular, antibiotics, gastroenterology, anti-diabetics, and anti-allergic therapeutic areas.

Números-chave

Capitalização de mercado: ₹998 billion
Receita (exercício encerrado em 2026-03-31): ₹333.8B
Lucro líquido: ₹35.0B
Margem bruta: 57.1%
Margem líquida: 10.5%

Ver gráficos interativos e demonstrações completas →

Demonstração de resultados anual

Demonstração de resultados	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Receita total	₹333.8B	₹313.8B	₹287.0B	₹246.2B
Lucro bruto	₹190.6B	₹176.4B	₹154.7B	₹127.2B
Resultado Operacional (EBIT)	₹51.9B	₹50.5B	₹44.4B	₹25.4B
Resultado líquido	₹35.0B	₹34.9B	₹31.7B	₹19.3B

Fonte: relatórios públicos da empresa (SEC). Verifique no SEC EDGAR antes de confiar em qualquer número.

Balanços, fluxos de caixa, dados trimestrais e indicadores completos no visualizador interativo de AUROPHARMA. /companies/us/AUROPHARMA

Empresas semelhantes

As informações deste site são apenas educacionais e informativas; não constituem recomendação de investimento. Não publicamos preços-alvo nem recomendações.

English version →Todas as ações

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.